IMGN529, an ADC, is a potential new treatment for patients with CD37-positive B-cell malignancies, such as non-Hodgkin lymphoma (NHL).

IMGN529 demonstrated initial evidence of anticancer activity in NHL in early clinical testing designed to establish its dose, and more data from this trial were reported at the American Society of Hematology meeting in 2014.

Preclinically, IMGN529 has shown synergy when administered with rituximab. A Phase 2 clinical trial is evaluating IMGN529 used with rituximab.

Last updated: May 9, 2016

You are now leaving this website. If you would like to continue, click Continue.